Member Bibliography/Bibliografía de Miembros
This page collects all the personal publications that CienciaPR members have uploaded to their profiles. You can also see all of the authors collected in these publications or all the keywords contained in these publications.
“Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.”, P R Health Sci J, vol. 33, no. 3, pp. 97-104, 2014.
“Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.”, Drug Metabol Drug Interact, 2014.
“CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters?”, Biomark Med, vol. 7, no. 6, pp. 913-4, 2013.
“Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population.”, J Pharmacogenomics Pharmacoproteomics, vol. 4, no. 113, 2013.
“Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients.”, Pharmacogenomics, vol. 13, no. 16, pp. 1937-50, 2012.
“Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.”, Ann Pharmacother, vol. 46, no. 2, pp. 208-18, 2012.
“CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.”, Clin Chim Acta, vol. 411, no. 17-18, pp. 1306-11, 2010.
“For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription.”, Ethn Dis, vol. 19, no. 4, pp. 479-80, 2009.
“Physiogenomic analysis of the Puerto Rican population.”, Pharmacogenomics, vol. 10, no. 4, pp. 565-77, 2009.
“Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.”, Ethn Dis, vol. 19, no. 4, pp. 390-5, 2009.
“Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report.”, P R Health Sci J, vol. 27, no. 4, pp. 357-8, 2008.